Dysport® + Bracing for Adolescent Idiopathic Scoliosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for adolescent idiopathic scoliosis, a condition where the spine curves in children for no known reason. Researchers are testing whether combining botulinum toxin A (Dysport®) injections with back bracing improves outcomes compared to bracing with a placebo. Participants will receive either Dysport® or a placebo along with their brace. The trial seeks children aged 10 to 16 with a specific type of scoliosis curve who have not recently received botulinum toxin treatment. As a Phase 4 trial, this research aims to understand how the already FDA-approved and effective treatment benefits more patients.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking drugs that interfere with neuromuscular function.
What is the safety track record for Dysport® and bracing in treating adolescent idiopathic scoliosis?
Research has shown that Dysport®, a type of botulinum toxin A, is generally safe for people. This treatment has been studied in various contexts and received FDA approval for conditions like muscle stiffness, indicating it has passed strict safety tests for those uses. In past studies with children, Dysport® was found to be safe, though it can have side effects like any treatment. These may include mild pain or swelling at the injection site, headache, or muscle weakness. Serious side effects are rare. This trial tests Dysport® along with bracing to assess its effectiveness for scoliosis in children. As a Phase 4 trial, the treatment is already approved, and the goal is to understand its effects better.12345
Why are researchers enthusiastic about this study treatment?
Researchers are excited about using Dysport® (a form of botulinum toxin) for treating adolescent idiopathic scoliosis because it offers a novel approach by targeting the muscles directly. Unlike the standard treatment options, such as bracing, which focus on external support, Dysport® works by relaxing the muscles on the concave side of the spinal curve, potentially reducing the curve's progression. This direct muscle action could complement existing methods, providing a more comprehensive approach to managing scoliosis. Additionally, Dysport® is administered via injection, which may offer a more targeted and less invasive alternative to surgical options.
What evidence suggests that Dysport® combined with bracing could be effective for adolescent idiopathic scoliosis?
Research has shown that botulinum toxin A, such as Dysport®, can reduce excessive muscle activity. This reduction may help manage spinal scoliosis by decreasing the spine's curvature. In this trial, one group of participants will receive Dysport® injections into specific back muscles. Previous studies found that these injections slowed the progression of the curve in adolescents with idiopathic scoliosis. This suggests that using Dysport® alongside bracing treatments could enhance the effectiveness of bracing. Overall, Dysport® supports existing scoliosis treatments by targeting the muscles that contribute to the curve.15678
Who Is on the Research Team?
Varun Puvanesarajah, MD
Principal Investigator
Johns Hopkins Hospital Department of Orthopaedic Surgery
Paul Sponseller, MD, MBA
Principal Investigator
Johns Hopkins Hospital Department of Orthopaedic Surgery
Are You a Good Fit for This Trial?
This trial is for children aged 10-16 with adolescent idiopathic scoliosis, where the curve is below the T7 vertebra and measures 20°-40°. They should have no prior botulinum toxin treatment in the last 6 months, be able to follow a bracing protocol, and not have had spine surgery or need it currently. Kids with congenital or neuromuscular scoliosis, ongoing infections at potential injection sites, cow milk protein allergy, or on drugs affecting muscle function can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Dysport® or placebo injections in the paraspinal musculature and are treated with bracing
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AbobotulinumtoxinA
- Custom Thoracolumbosacral Orthosis
- Placebos
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor